Please read the PCOA Registration and Administration Guide for Schools and Colleges of Pharmacy (referred to as PCOA Registration and Administration Information (PRAI) in the Memorandum Of Understanding) thoroughly to ensure that you understand all the policies and procedures for registering for and administering the assessment. This guide contains information for all administrations of the PCOA beginning January 2019.
Mission Statement of the National Association of Boards of Pharmacy

NABP Mission Statement
NABP is the independent, international, and impartial Association that assists its member boards and jurisdictions for the purpose of protecting the public health.
# Table of Contents

**Introduction** ................................................................................................................................ 4  
Welcome to the PCOA ................................................................................................................ 4  
Foundation of the PCOA ......................................................................................................... 4  
Contact Information .............................................................................................................. 5  

**Registering for the PCOA** ....................................................................................................... 6  
Testing Windows for the 2019 PCOA .................................................................................. 6  
Administration Facility Requirements .................................................................................... 7  
On-Site School/College Contact ............................................................................................. 7  
On-Site Technical Representative ......................................................................................... 7  
Assessment Fees ..................................................................................................................... 7  
Student Registration ............................................................................................................... 8  

**ADA Testing Accommodations** .............................................................................................. 10  

**Administering the PCOA** ......................................................................................................... 12  
Technical Requirements ........................................................................................................ 13  
Installing FastTest WebLock .................................................................................................. 14  
Removing FastTest WebLock ................................................................................................. 15  

**PCOA Content Areas** ............................................................................................................. 16  
PCOA Item Types .................................................................................................................... 20  
Multiple-Choice Question Format ......................................................................................... 20  
Multiple-Response Question Format ..................................................................................... 20  
Constructed-Response Question Format ............................................................................... 20  
Ordered-Response Question Format ...................................................................................... 21  
Hot Spot Question Format .................................................................................................... 22  

**PCOA Practice Test** ............................................................................................................... 23  

**Accessing and Understanding PCOA Scores** ...................................................................... 24  
Accessing Score Reports ......................................................................................................... 24  
Individual (Student) Score Reports .......................................................................................... 24  
Roster Reports ........................................................................................................................ 24  
School/College of Pharmacy Reports ...................................................................................... 24  
Understanding PCOA Results .................................................................................................. 25  
Question and Exam Development ............................................................................................ 25  
Validity Framework ................................................................................................................ 25  
NABP Analyses ....................................................................................................................... 26  

**Appendices** ............................................................................................................................ 27  
Appendix A: Glossary of Important Terms for the PCOA Scores ........................................ 27  
Appendix B: Important Dates for the 2019 PCOA .................................................................. 28  
Appendix C: Student Score Report Sample .......................................................................... 29  
Appendix D: School/College Score Report Sample ................................................................ 31  

**PCOA School/College Registration Form** ............................................................................ 34
Introduction

Welcome to the PCOA

The Pharmacy Curriculum Outcomes Assessment® (PCOA®) is a comprehensive tool developed by the National Association of Boards of Pharmacy® (NABP®) to provide an independent, objective, and external measure of student performance in United States pharmacy curricula.

The PCOA is suitable for students in all professional years and provides data to the schools and colleges that may facilitate review of an individual student’s performance and progress from year to year in relation to the curriculum. The PCOA also provides data on national results for comparison. As part of the schools and colleges of pharmacy commitment to continuous improvement, the PCOA may help evaluate if a school’s curriculum is meeting the desired outcomes of its doctor of pharmacy program.

Foundation of the PCOA

The foundation of the PCOA is a set of competency statements that reflect the Accreditation Council for Pharmacy Education (ACPE) Standards 2016, Appendix 1 (Required Elements of the Didactic Doctor of Pharmacy Curriculum), and the Center for the Advancement of Pharmacy Education (CAPE) Educational Outcomes. The competency statements are reviewed by faculty from US schools/colleges of pharmacy every four to five years. These competency statements are also used to create a survey of curricula among US school/college of pharmacy programs. Survey results are used to create weights for the competency statements, which drive the PCOA blueprint and determine the number of questions on each topic to be covered in the assessment.

Additional details, including an outline and description of the PCOA content domains can be found beginning on page 16 of this guide. Examples of the item types are available on page 20 of this guide and on the NABP website at www.nabp.pharmacy.

Note: The PCOA contents including, without limitation, questions and answers are copyrighted by NABP and are the exclusive property of NABP.
Contact Information

Schools and colleges of pharmacy with questions regarding materials or administration of the PCOA may use the following contact information.

Nancy Rutter, FPGEC/PCOA Program Analyst
Telephone: 847/391-4447
Email: PCOA@nabp.pharmacy
Registering for the PCOA

Prior to registering for a PCOA administration, schools and colleges of pharmacy must execute a memorandum of understanding (MOU) with NABP. All schools and colleges that participated in the PCOA in 2016 have completed MOUs, which remain in effect. If your school has not completed the MOU with NABP, please contact the NABP Legal Affairs department for further information by sending an email to legalaffairs@nabp.pharmacy.

The 2019 PCOA will be administered during five testing windows. To participate, schools or colleges of pharmacy must submit a completed registration form prior to the registration deadline for the desired testing window (dates are noted below).

- A registration form must be completed for each session to be conducted at one time in one building.
- Schools and colleges must indicate the following on the registration form:
  » selected testing date(s) and times; the date(s) must fall within the available testing windows
  » site where the PCOA will be administered
  » number of students, by professional year, who will be sitting for the PCOA (see Assessment Fees in this section for more information)
  » selected responses on page 2 regarding reporting scores to the Accreditation Council for Pharmacy Education as well as Americans with Disabilities Act (ADA) testing accommodations, along with the estimated number of students
- All three pages of the registration form must be submitted to the email address noted below.

Note: To ensure appropriate reporting of scores and related invoicing, please indicate any cohort of students nearing the end of their didactic curriculum as P3. Each session must have a minimum of 20 students.

The PCOA Registration Form is a fillable PDF that may be downloaded from the NABP website. It is available at www.nabp.pharmacy under PCOA in the Programs section of the site. The form is also included at the end of this guide. A form must be submitted to NABP for each testing session.

Testing Windows for the 2019 PCOA

<table>
<thead>
<tr>
<th>2019 Testing Windows</th>
<th>School COLlege Registration Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 14 – February 15</td>
<td>October 16, 2018</td>
</tr>
<tr>
<td>April 8 – May 17</td>
<td>January 8, 2019</td>
</tr>
<tr>
<td>June 17 – June 28</td>
<td>March 19, 2019</td>
</tr>
<tr>
<td>August 19 – September 13</td>
<td>May 21, 2019</td>
</tr>
<tr>
<td>November 11 – December 13</td>
<td>August 13, 2019</td>
</tr>
</tbody>
</table>

* A detailed timetable, including the student registration deadline and all other deadlines related to each testing window, is available on page 28 of this guide.

Important:

» NABP is unable to accommodate testing dates outside of the testing windows above. In addition, NABP will be unable to process registrations for a testing window after the corresponding registration deadline has passed.
» The PCOA may only be scheduled Monday through Friday.

Using the contact information below, please email the completed registration form to NABP by the registration deadline of the preferred testing window. NABP will confirm the PCOA date via email within one week of receipt.
Email: PCOA@nabp.pharmacy  
Attn: Nancy Rutter, FPGEC/PCOA Program Analyst

Administration Facility Requirements

Schools and colleges of pharmacy must indicate on their PCOA registration form the room or rooms that will be used for the PCOA administration. Acceptable testing sites include classrooms, conference rooms, auditoriums and theatres, or on-campus computer labs. Acceptable testing sites must have continuous internet connectivity. See technical requirements on page 12 for more information.

It is the responsibility of the schools and colleges to ensure that the facilities reserved for the assessment can accommodate the number of students registered to take the PCOA. Changes in facilities after the registration deadline will incur an administrative fee.

**Note:** No changes or additions to facilities shall be made within two weeks of the start of a testing window.

Students will have three hours to complete the assessment; however, you should schedule the testing room for a minimum of four hours to allow for student check-in, seating, and post-assessment cleanup.

**Note:** Additional check-in time may be needed for larger cohorts testing.

**Note:** It is recommended that any events held for students participating in the PCOA be scheduled after the completion of the assessment.

On-Site School/College Contact

Schools and colleges must also indicate on the PCOA registration form their designated on-site contact. All updates and inquiries regarding the administration will be directed to this representative, and he or she will be required to be accessible during the PCOA administration. In addition, each contact person must be present during the student check-in process and at the conclusion of the assessment.

**Note:** NABP will contract with a testing vendor who will be responsible for overseeing the administration of the PCOA. The test site administrator (TSA) will be responsible for the on-site student registration/check-in, as well as the proctoring of the assessment.

On-Site Technical Representative

Schools and colleges must indicate an on-site technical representative who is knowledgeable of the school’s hardware and network systems and who will be present at the administration of the assessment. NABP will provide detailed system requirements for the WebLock software to your representative prior to the assessment.

Assessment Fees

The PCOA is provided at no cost for students nearing the completion of their didactic curriculum. Please note that students in this group qualify to take the assessment one time at no cost. If the school/college chooses to schedule additional administrations, a fee of $75 per student will apply. The assessment fee per student in other curriculum years is also $75.

**Note:** Students nearing the completion of their didactic curriculum must be designated as P3s in order to test at no cost. Failure to appropriately identify a cohort as P3 will result in the school/college being invoiced at $75 per student. The P3 designation is solely used to track the cohort for record keeping and reporting purposes only. NABP fully understands that each program may categorize the group of students near the end of didactic curriculum in other manners for internal identification.
Beginning January 1, 2018, the schools and colleges of pharmacy will be assessed a $25 administrative fee for all accommodated changes that occur after the registration deadline, including:

- additions/deletions to the registration roster ($25 per student added or removed)
- assessment logistics (addition of rooms or changes to site location)
- requests for testing accommodations in compliance with the Americans with Disabilities Act (ADA) submitted after the deadline as outlined on page 10 of this Guide.

A PCOA administration cancelled due to non-natural causes, including, but not limited to, the unavailability of a continuous internet connection or room scheduling conflicts at the school, will be assessed with a $1,500 cancellation fee. To avoid any unnecessary fees, please work with your staff to organize efforts regarding the PCOA administrations.

If applicable, NABP will invoice the school/college after the completion of the PCOA. Schools and colleges should indicate invoicing information in the “Payment Information” section of the PCOA registration form. A purchase order may be submitted prior to the date of the assessment and NABP will invoice against the purchase order.

**Important:** Failure to remit administrative fees may result in a hold on score reporting to the students, schools, and the Accreditation Council for Pharmacy Education.

**Student Registration**

Once your PCOA administration date has been confirmed by NABP, please advise your students to register online for the PCOA (see below for instructions). Administration dates are typically confirmed within five business days of receiving the school/college registration form. A flyer providing students a brief overview of the PCOA and informing them how to register has been provided to assist with the student registration process. The student flyer is also available in the PCOA section of the NABP website and may be downloaded for distribution to students. Students will not be asked for payment information during the online registration process.

**Important:** Students must complete their registration at least 60 days prior to the start of the testing window. Students who do not register online for the PCOA will not be permitted to test.

Once registered, the name of each student from your school/college will appear on the preliminary roster provided through NABP e-Profile Connect.

**Student Registration Process**

Students must create an NABP e-Profile and use the e-Profile to register for the PCOA. Students should follow the instructions below:

**Note:** Google Chrome is the recommended web browser to create an e-Profile ID and register for the PCOA.

1. **Create an NABP e-Profile**

   Visit [www.nabp.pharmacy](http://www.nabp.pharmacy) and click on the “NABP e-Profile Login” hyperlink located at the top, right-hand corner of the NABP home page. From the dashboard, select the “Customers” button. Then select the “Create a login” hyperlink.

2. **Set Up Login Credentials**

   On the next screen, enter your email address and select the “Next” button. A verification code will be sent to the email address you just entered. Enter the verification code within 30 minutes and create a new password. Confirm your password and select the “Create Login” button.

   **Note:** Students are strongly encouraged to use their school email address.

You will be returned to the main login screen, where you can enter your email address and newly created password. Then select the “Sign In” button.
On the next screen, select the “Create e-Profile” button and follow the prompts to complete the creation of your e-Profile and obtain your e-Profile ID.

3. Enter Personal Information

During the e-Profile verification and creation process, you will be asked to input or review personal data. The data required for an e-Profile include: legal name, gender, profession, date of birth, Social Security number, address, and phone number. Have this information ready when you are creating or verifying your account.

**Important:**
- Select “Pharmacist Student” as your profession. This will allow you to register for the PCOA. Selecting any other choice will block you from registering for the PCOA.
- Mistakes in data entry for legal name, date of birth, or Social Security number will require a submission of documentation to NABP Customer Service to be corrected.
- Your name must be entered exactly as it appears on your state-issued photo identification. You must enter last, first, and middle name or initial, and suffixes exactly as they appear on your identification.
- A Social Security number is required to create an e-Profile. If you do not have a Social Security number, you must contact NABP Customer Service, Monday through Friday, 9 AM to 5 PM Central Time, at 847/391-4406, or by email at help@nabp.pharmacy.

4. Obtain Your e-Profile ID

Once all your data is entered, you will be taken to an e-Profile Account Confirmation screen. Save your NABP e-Profile ID number for future reference. To complete your registration, click on “Go to Dashboard” and follow the instructions in Step 5.

5. Register for the PCOA

Go to the e-Profile dashboard and select “Exam Services.” Then on the next screen, select the “PCOA Register” button. To complete the registration process:

a. Read the Terms of Service. Select the box to acknowledge and accept the Terms of Service. You will be unable to continue without accepting these terms.

b. Enter information about your education on the following screen.

c. If applicable, download the Americans with Disabilities Act (ADA) request form to be completed and submitted to the school.

d. Review your application information on the following screen and click Submit.

e. Receive an order confirmation on the Exam Services screen. Scroll down to view your registration information.
ADA Testing Accommodations

NABP is responsible for meeting the requirements of the Americans with Disabilities Act (ADA) and its amendments and any other federal or state laws that require accommodations for qualified disabled candidates in the administration of the PCOA, including establishing and assessing an individual's disability and evaluating what accommodations are necessary and reasonable under the circumstances. NABP must ensure that accommodations do not place the security of the PCOA in jeopardy or affect the validity or integrity of the PCOA, or its ability to assess the individual's performance as described herein. NABP will review each accommodation request and will approve or deny the request. NABP is responsible for bearing the cost of providing approved accommodations.

To submit an accommodation request, the student must download, print, and complete the three-section Request for Disability Accommodations form. Students can find a link to the form under “PCOA for Students” in the Programs section of the NABP website. The student should complete Section I, Individual's Information, of the form and have their practitioner complete Section II.

The student must then submit the request form, with Sections I and II completed, to the school/college for the school/college to complete Section III: Academic/School or College Information. The student is responsible for timely submitting the request.

Note: A completed ADA request form is required each time a student registers for the PCOA.

The school/college must then submit the completed ADA request form (Sections I, II, and III) using NABP e-Profile Connect no less than 45 days prior to the start of the school/college’s selected testing window.

The completed request form must include Parts I-III. More details about Parts I-III are described below and on page 11.

- Part I – Individual's Statement
- Part II – Practitioner's Statement and Diagnostic Results with a separate written practitioner's statement
- Part III – Academic/College Information

I. Individual's Statement
   a. A detailed report written by the individual describing the disability, requested accommodations, and treatment prescribed.

II. Practitioner's Statement and Diagnostic Results
   1. Each provider is required to complete Part II of the ADA request form “Practitioner's Statement” including the date of the initial diagnosis, date last evaluated, and the length of time as a patient.
      i. The practitioner must provide documentation of credentials supporting the diagnosis(es) and recommendation.
      ii. A statement of the specific diagnosis of the disability is required. A professionally recognized diagnosis for each category of disability is expected. The supporting written statement is required to explain the recommended accommodation. The attached document should be typed on identifying letterhead and signed by the practitioner.
      iii. A written explanation should be provided if no history of accommodations was required in similar or past testing environments. The explanation should account for any disability that is not permanent or long-lasting.
      iv. Describe any treatment for the disability or condition prescribed (e.g., any medication management regimens or physical aids).
2. Diagnostic tests to support requests. Current diagnostic tests, as applicable, and relevant medical history should be submitted. In most cases, an evaluation should have been conducted within the past three years. Specific tests should support the diagnosis and recommendation.

III. Academic/School or College Information

a. Pursuant to the student authorization and release, the school/college is required to provide documentation of accommodations provided in a testing environment, including the frequency of accommodations.

**Important:** Testing accommodation requests that are unreasonable, would fundamentally alter the nature or integrity of the examination, would jeopardize examination security, or that would impose an undue burden on NABP or other candidates will be subject to denial.

NABP will review the request and will notify the school/college regarding the coordination of the request. **Arrangements for accommodations can only be made if NABP is notified no less than 45 days prior to the start of your preferred testing window.** There are no exceptions to this policy.

**Important:** The school/college is responsible for securing the appropriate number of rooms to accommodate students requesting a separate testing space. This space should be in the same building where the rest of the cohort is testing. In some instances it may be appropriate for all students requiring a separate room to all test in one room.
Administering the PCOA

The school/college provides the PCOA test location and the physical facilities needed to assist NABP in securely administering the PCOA to the students.

NABP may contract with a testing vendor who will be responsible for overseeing the administration and proctoring of the PCOA. The Test Site Administrator (TSA) will arrange a meeting with the school/college contact approximately one week prior to the scheduled assessment day to confirm arrangements and test day schedule.

Each school/college contact must be present during the student check-in and at the conclusion of the assessment. It is imperative that a technical support person is on the premises during the assessment. The TSA will be responsible for overseeing the on-site student registration/check-in, as well as the proctoring of the assessment.

The school/college is expected to provide the following resources for all administrations, without charge to NABP:

- Assigned assessment room(s); rooms must be made available at least 30 minutes prior to student reporting time
- Registration area in each facility with table(s) and chairs
- Protocol for emergency situations
- A technical support person
- Continuous internet access and power for all students
- Additional laptops or computers in case of technical issues.
- Ensure that the FastTest WebLock software has been pre-installed on laptops-desktops in an on-campus computer lab.

The TSA and proctors will arrive at minimum one hour prior to the scheduled start of the PCOA to set up. Student check-in should begin 30 minutes prior to the assessment start time. However, those schools/colleges with a large number of participating students may need to allow additional time for check-in. As the student is checked in, they will be provided with a work paper that contains their unique computer login information for the assessment. The proctors will then seat each student in the designated room(s).

To ensure that assessment results for all students are earned under comparable conditions and represent fair and accurate measurement of each student’s individual knowledge and skills, it is necessary to maintain a standardized and secure testing environment. All students must adhere to the following policies:

- No reference, study, or other materials or devices may be brought into the testing room.
- Prohibited items will not be allowed into the testing room. Prohibited items include, but are not limited to, the following:
  - Books, reference, or study materials
  - Book bags, backpacks, briefcases, handbags/purses, tote bags, computer bags
  - Calculators
  - Cell phones, pagers, Bluetooth ear pieces
  - Food
  - Glasses or any other device with a camera (such as Google Glass)
  - Other electronic or digital devices (watches, activity wristbands, PDAs)
  - Outerwear (coats, hats)
  - Photographic devices
  - Recording devices
  - Weapons

A place for students to place these items will be designated either inside or outside of the assessment room.
The PCOA is the property of NABP and is protected by copyright law, and other applicable state and federal laws and regulations. Students taking the PCOA are expressly prohibited from offering, disclosing, publishing, reproducing, transmitting, receiving, utilizing, or making available the PCOA including, but not limited to, examination question format, examination questions, profiles, and scenarios, in whole or in part, in any form or by any means, whether verbal, written, electronic, or mechanical for any purpose. Testing proctors will enforce security measures to ensure the integrity of the PCOA and the PCOA program. Students should be observed at all times while taking the PCOA.

If an individual engages in misconduct, NABP may terminate the assessment administration for the individual.

In the event of any serious breach of the security or integrity of the PCOA, regardless of who caused it or how, NABP may, in its sole discretion, suspend administration of the PCOA.

**Technical Requirements**

Each student sitting for the PCOA must have access to a personal or university-issued laptop or desktop computer. Computers must have continuous power and internet connectivity available (DSL or internet speed equivalent to 1.5 megabits per second or higher). Schools should ensure that adequate bandwidth is available for the number of students taking the examination.

For security purposes, NABP uses the FastTest WebLock browser, which prohibits access to other Internet browsers and other software until the assessment is completed and submitted. To ensure seamless delivery of the PCOA on testing day, this browser must be downloaded and installed before the examination. It is strongly recommended that it be installed at least one day prior to the testing day to avoid any issues on the day of the PCOA. Downloading the browser ahead of time will not impair the functionality of the computer for any other applications.

Taking the PCOA requires one of the following internet browsers:

- The current version of Mozilla Firefox
- The current version of Google Chrome
- The current version of Apple Safari
- The current version of Microsoft Edge

In addition, test takers should make sure their computers have the following:

- Adobe Flash Plug-in, version 9.0.115 or newer
- JavaScript enabled
- Cookies enabled
- Screen resolution set to 1024x768 or higher

**Note:** Virtual desktops, tablets, and other mobile devices cannot be used for the PCOA at this time.

For the most up-to-date technical requirements, please refer to the System Requirements section, which can be accessed through the Examinee Login page of the WebLock browser.

At least two weeks in advance of your scheduled administration date, NABP will send instructions for the WebLock browser to your students. We strongly recommend the student monitor the email address with which they registered for the PCOA for this communication, as well as monitor their spam folder.

So that each student can log in to take the PCOA on the testing day, during check-in the vendor gives each examinee a test code that is unique to them.
Installing FastTest WebLock
The following describes how to install the WebLock browser on a computer, deliver a test in WebLock, and remove WebLock afterward.

Install WebLock on Each Computer
1. Before you start, ensure that:
   - You have administrative rights on the computer that will be used;
   - The computer is connected to the internet;
   - All other programs are closed on the computer; and
   - For installation on a Mac, the latest version of Java must be installed on the computer.

   **Note:** The installation should be completed in advance to ensure that the computer is ready on testing day.

2. Visit [https://weblock.fasttestweb.com/testing/pr/20/9](https://weblock.fasttestweb.com/testing/pr/20/9).
3. Click on “Click here to install the FastTest WebLock secure browser” on the left side of the screen.

4. Run the program and click “Yes” or “Continue” for all prompts. The installation will check whether you have Microsoft Windows or an Apple Mac operating system and install appropriately.

5. If prompted, click the “Run” button or open WebLockSetup.exe when it has finished downloading. The setup installer will launch.

6. Your computer may ask you to confirm that you want to run the software. Click “Run” or “Yes” to continue.

   **Note:** Steps 4-6 will differ depending on the browser and operating system you are using. For example, in step 4, older versions of Internet Explorer will display a pop-up box to confirm the download, while newer versions may ask for confirmation on a bar at the bottom of the browser window. If you are unable to download WebLock, you may need to consult your browser’s help system.
7. The installer will then open. Click “Next.”
8. Click “Next” to install the program in the default folder.
9. Click “Install” to run the installer.
10. Click “Finish” to close the installer and return to the browser.

Verify Installation

To verify that the WebLock browser is properly installed on your computer, confirm the installation by clicking on this link using Google Chrome or Mozilla Firefox: weblock.fasttestweb.com.

Removing FastTest WebLock

You can remove WebLock if the individual computer is only being used for one test and no other test will be given via WebLock.

1. Click on Start > Control Panel > Uninstall a Program.
2. Select FastTest WebLock from the list of programs.
3. Click Uninstall.
4. Follow the on-screen prompts to remove the program.
The PCOA content areas and subtopics for the 2018-2019 administration are based upon the outcomes from the US College of Pharmacy Curricula Survey. The assessment is composed of four content areas that are broken down into 28 subtopic areas.

For a representative sample of the item types, see page 20 of this guide.

The 2018-2019 PCOA blueprint calls for each assessment form to meet the following distribution of questions:

<table>
<thead>
<tr>
<th>Main Content Domain</th>
<th>% of Operational Items</th>
<th># of Operational Items</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Biomedical Sciences</td>
<td>10%</td>
<td>20</td>
</tr>
<tr>
<td>Pharmaceutical Sciences</td>
<td>33%</td>
<td>66</td>
</tr>
<tr>
<td>Social/Behavioral/Administrative Sciences</td>
<td>22%</td>
<td>44</td>
</tr>
<tr>
<td>Clinical Sciences</td>
<td>35%</td>
<td>70</td>
</tr>
<tr>
<td><strong>Totals</strong></td>
<td><strong>100%</strong></td>
<td><strong>200</strong></td>
</tr>
</tbody>
</table>

**Area 1.0 – Basic Biomedical Sciences 10%**

1.1 **Physiology**

1.1.1 Function of the major body systems and homeostatic impact at organ and system level

1.2 **Biochemistry**

1.2.1 Chemistry and utilization of biomacromolecules including proteins, lipids, carbohydrates, nucleic acid, intermediary metabolism of energy and nutritional molecules

1.2.2 Enzymology and coenzymes and kinetics

1.2.3 Cell chemistry, signal transduction pathways

1.2.4 Transport and mobility

1.2.5 Recombinant DNA and molecular biotechnology

1.2.6 mRNA translation and protein synthesis

1.3 **Microbiology Related to Human Disease**

1.3.1 Structure, function, and characteristics of microorganisms: microbe classification, structure, metabolism, genetics

1.3.2 Pathogenic microorganisms of humans

1.4 **Immunology**

1.4.1 Innate and adaptive immunity

1.4.2 Principles of antibody actions

1.4.3 Hypersensitivity and types of reactions

**Area 2.0 – Pharmaceutical Sciences 33%**

2.1 **Medicinal Chemistry**

2.1.1 Physicochemical properties of drugs in relation to drug absorption, distribution, metabolism, and excretion (ADME)

2.1.2 Chemical basis for drug action

2.1.3 Fundamental pharmacophores for drugs used to treat diseases

2.1.4 Structure-activity relationships in relation to drug-target interactions

2.1.5 Chemical pathways of drug metabolism

2.1.6 Applicability to making drug therapy decisions
2.2 **Pharmacology and Toxicology**
   2.2.1 Mechanisms of action of drugs of various categories including biologics
   2.2.2 Pharmacodynamics of drug binding and response
   2.2.3 Adverse effects and side effects of drugs
   2.2.4 Mechanisms of drug-drug interactions
   2.2.5 Drug discovery and development
   2.2.6 Acute and chronic toxic effect of xenobiotics, including drug and chemical overdose and antidotes

2.3 **Pharmacognosy and Dietary Supplements**
   2.3.1 Concepts of crude drugs, semi-purified, and purified natural products
   2.3.2 Classes of pharmacologically active natural products
   2.3.3 Science and regulation of dietary supplements (vitamins, minerals, and herbals)

2.4 **Pharmaceutics/Biopharmaceutics**
   2.4.1 Biopharmaceutical principles of drug delivery to the body via dosage forms: liquid, solid, semisolid, controlled release, patches, implants
   2.4.2 Materials and methods used in preparation of drug forms
   2.4.3 Physicochemical properties relating to drug entities and dosage forms
   2.4.4 Principles of drug and dosage form stability, including chemical degradation and physical instability

2.5 **Pharmacokinetics**
   2.5.1 Basic principles of in-vivo drug kinetics (linear and nonlinear)
   2.5.2 Principles of bioavailability and bioequivalence
   2.5.3 Physiologic determinates of drug onset and duration, including disease and dietary influences on absorption, distribution, metabolism, and excretion

2.6 **Pharmacogenomics and Genetics**
   2.6.1 Molecular genetics, genomic, proteomic, and metabolomic principles that serve as a foundation for pharmacogenomics and the genetic basis of disease
   2.6.2 Genetic variants affecting drug action and metabolism, adverse drug reactions, and disease risk that influence the practice of personalized medicine

2.7 **Sterile and Nonsterile Compounding**
   2.7.1 United States Pharmacopeia guidelines on sterile and nonsterile compounding, hazardous drugs, and FDA regulation of compounding
   2.7.2 Techniques and principles used to prepare and dispense individual extemporaneous prescriptions, including dating of compounded dosage forms
   2.7.3 Dosage form preparation calculations
   2.7.4 Sterile admixture techniques, including stability, clean-room requirements, sterility testing, and dating

**Area 3.0 – Social/Behavioral/Administrative Sciences 22%**

3.1 **Health Care Delivery Systems and Public Health**
   3.1.1 Organization of health care delivery systems at the national, state, and local levels: various settings where pharmacy is practiced and the structure of health care delivery systems such as managed care organizations, accountable care organizations, health departments
   3.1.2 Health care delivery financing in the United States
   3.1.3 Social, political, and economic factors that influence the delivery of health care in the United States
   3.1.4 Public Health and Wellness: chronic disease prevention, health promotion, infectious disease control, demographics, physical, social, and environmental factors leading to disease, comparing and contrasting public health with individual medical care
   3.1.5 The health care delivery system compared and contrasted with that of other industrialized nations
3.2 Population-based Care and Pharmacoepidemiology
3.2.1 Data sources and analytic tools that provide an estimate of the probability of beneficial or adverse effects of medication use in large populations
3.2.2 Application of epidemiological study designs to evaluate drug use and outcomes in large populations
3.2.3 Methods for continually monitoring unwanted effects and other safety-related aspects of medication use in large populations

3.3 Economic and Humanistic Outcomes of Health Care Delivery
3.3.1 General microeconomic and general macroeconomic principles
3.3.2 Pharmacoeconomic analysis and its application to improve the allocation of limited health care resources
3.3.3 Humanistic outcomes and their application to improve the allocation of limited health care resources

3.4 Pharmacy Practice Management
3.4.1 Management principles (planning, organizing, directing, and controlling pharmacy resources) applied to various pharmacy practice setting and patient outcomes
3.4.2 Personnel management
3.4.3 Planning, including delineation between business and strategic planning
3.4.4 Marketing of goods and services: product versus service pricing, distribution, promotion
3.4.5 Accounting and financial management
3.4.6 Budgeting
3.4.7 Risk management

3.5 Pharmacy Law and Regulatory Affairs
3.5.1 Legal and regulatory principles applied to pharmacy practice: dispensing, professional services, drug use control
3.5.2 Administrative, civil, and criminal liability
3.5.3 Authority, responsibilities, and operation of agencies and entities that promulgate or administer laws, regulations, or guidances related to practice and prescription and nonprescription medications

3.6 Biostatistics and Research Design
3.6.1 Research study designs used in medical research
3.6.2 Application and interpretation of statistical tests and data collection instruments

3.7 Ethical Decision Making
3.7.1 Principles of biomedical ethics
3.7.2 Ethical dilemmas in the delivery of patient, centered care including, conflicts of interest, end-of-life decision making, use of codes of ethics, oaths of the pharmacist
3.7.3 Research ethics

3.8 Professional Communication
3.8.1 Communication abilities (appropriate verbal, nonverbal, visual, and written) with patient and caregivers, including empathetic communication
3.8.2 Communication abilities with other health care providers
3.8.3 Assertiveness and problem-solving techniques in relation to difficult social and professional conflicts and situations
3.8.4 Measurement and use of health literacy in pharmacy communications
3.8.5 Development of cultural competency in pharmacy personnel such that services are respectful of and responsive to the health beliefs, practices, and cultural and linguistic needs of diverse patient populations
3.9  **Social and Behavioral Aspects of Pharmacy Practice**
- 3.9.1 Health-, illness-, and sick-role behaviors of patients
- 3.9.2 Principles of behavior modification
- 3.9.3 Patient adherence to therapies and recommendations
- 3.9.4 Caregiving throughout the lifecycle
- 3.9.5 Death and dying

3.10  **Medication Dispensing and Distribution Systems**
- 3.10.1 Systems for safe and effective preparation and dispensing of medications in all types of practice settings
- 3.10.2 Role of automation and technology: pharmacy informatics, information management
- 3.10.3 Continuous quality improvement programs or protocols in the medication-use process, including identification and prevention of medication errors, and establishment of error reduction programs

**Area 4.0 – Clinical Sciences 35%**

4.1  **Evidence-based Practice**
- 4.1.1 Interpret and evaluate drug information
- 4.1.2 Apply drug-information skills for the delivery of medication therapy management
- 4.1.3 Evaluate the reliability of various sources of information
- 4.1.4 Interpret guidelines as they apply in a clinical setting
- 4.1.5 Utilize core scientific and systems-based knowledge in the patient care decision-making process
- 4.1.6 Utilize basic science principles in the development and/or implementation of drug treatment protocols and clinical practice guidelines
- 4.1.7 Evaluate clinical trials that validate clinical appropriateness

4.2  **Clinical Pathophysiology**
- 4.2.1 Apply concepts of pathophysiology to clinical decision making

4.3  **Clinical Pharmacokinetics**
- 4.3.1 Utilize pharmacokinetics to calculate, evaluate, and individualize drug therapy
- 4.3.2 Interpret clinical pharmacokinetics of commonly used and low-therapeutic-index drugs

4.4  **Clinical Pharmacogenomics**
- 4.4.1 Utilize pharmacogenomics to calculate, evaluate, and individualize drug therapy

4.5  **Disease Prevention and Population Health**
- 4.5.1 Recognize the proper use of nonpharmacologic therapies, including complementary and alternative medicines
- 4.5.2 Describe measures to promote wellness and disease prevention
- 4.5.3 Identify the role of immunizations in disease prevention and health promotion

4.6  **Patient Assessment**
- 4.6.1 Describe techniques for obtaining a comprehensive patient history
- 4.6.2 Describe how to perform patient physical assessments: inspection, palpation, percussion, auscultation
- 4.6.3 Differentiate between normal physical assessment findings and modifications caused by common disease states and drug therapy
- 4.6.4 Interpret common clinical laboratory values and diagnostic tests
- 4.6.5 Perform calculations related to patient assessment: BMI, CrCl, lab adjustments
- 4.6.6 Describe the use of OTC point-of-care testing devices: glucometers, pregnancy tests, home testing for HbA1c, drug screening
4.7 Clinical Pharmacology and Therapeutic Decision Making  
4.7.1 Make therapy recommendations based on dosage calculations, specific uses and indications of drugs, and nutritional and support therapy  
4.7.2 Interpret therapeutic drug concentrations  
4.7.3 Assess pharmacotherapy considering contraindications, therapeutic duplications, dietary interactions, adverse drug reactions and interactions, and allergies  
4.7.4 Triage and identify when to refer patients to other health professionals  
4.7.5 Design patient-centered, culturally-relevant treatment plans  
4.7.6 Apply evidence-based decision making to patient care  
4.7.7 Recommend nonprescription and natural product therapies  
4.7.8 Identify and manage drug toxicity, drug-induced diseases, and misuse or abuse  
4.7.9 Monitor drug therapy for misuse, abuse, and non-adherence  

PCOA Item Types  
The following are examples of item formats that a student may encounter when taking the PCOA. These questions are presented as examples to familiarize students with their formats and are not intended to represent content areas of the PCOA.  

Multiple-Choice Question Format  
Which of the following vaccines is contraindicated in immunocompromised patients?  
A. Pneumococcal polysaccharide  
B. Varicella  
C. Meningococcal conjugate  
D. Subcutaneous influenza  

Multiple-Response Question Format  
What counseling information should a pharmacist provide to a patient taking oral tacrolimus? (Select ALL that apply.)  
A. Avoid live virus vaccinations  
B. Avoid grapefruit and grapefruit juice  
C. If a dose is missed, double up on the next dose  
D. Do not drink alcohol while taking this medication  
E. Medication levels need to be monitored  

Constructed-Response Question Format  
Griseofulvin oral suspension contains 125 mg/5 mL. A physician prescribed 250 mg bid for 2 weeks for a patient. How many milliliters of griseofulvin should be dispensed in order to fill this prescription?  
(Answer must be numeric; round the final answer to the nearest WHOLE number.)
Ordered-Response Question Format

The following corticosteroids are formulated as topical ointments. Rank their potency from highest to lowest starting with the highest on top.

(ALL options must be used.)
Hot Spot Question Format

Which area is predominantly responsible for coordination of movement using skeletal muscles? (Place the cursor on the area to select, then click the left mouse button. To change your answer, move the cursor to another area and click.)
To help familiarize students with the types of questions and the format of the PCOA, as well as the FastTest WebLock software, NABP offers a 50-item PCOA Practice Test at no charge. Students who have registered for the PCOA will receive a practice test code and instructions for downloading FastTest WebLock in an email (to the address provided by the student at registration) approximately two weeks before the PCOA administration. The practice test may be taken only once.

Students who do not receive the email with the practice test code should be directed to check their spam filters. If no email has been received, please email the student’s name and email address to NABP at PCOA@nabp.pharmacy. A new practice code will be sent to the student. A spreadsheet will be sent to the school contact containing all students’ practice codes upon request. Please note that the PCOA email address is for use by schools/colleges only.

Responses will not be sent to students who request information through this email address.
Accessing and Understanding PCOA Scores

Accessing Score Reports

Individual student and school score reports are made available only to the school/college of pharmacy within two to three weeks after the assessment administration. Both student and school/college score reports may be accessed by the school via NABP e-Profile Connect. A roster of participating students and their respective scores will also be available. NABP will also provide a summary report to ACPE that will contain mean overall and domain-level scores for each participating school/college of pharmacy. Schools/colleges of pharmacy may use individual scores, overall and domain-level scores, percentile ranks, scaled and national scores, and “normed” scores provided by NABP for analysis, research, education, and other lawful purposes.

The school/college of pharmacy is responsible for the distribution of individual reports to the students. NABP will maintain the data collected through the administration of the PCOA for Association use and will not disclose any identifiable data except as stated in this guide, as required by law, or as permitted by the student.

Individual (Student) Score Reports

Student score reports are produced for each participating student and include the student’s name, program year, sponsoring institution, test window of administration, and scores. Scaled scores and corresponding percentile rank scores are produced as an overall measure of proficiency as well as proficiency measures for each of the four major content areas. Scaled scores range from a minimum of 0 to a maximum of 700.

In addition to overall and domain-level scores and percentile ranks, percent-correct scores (and the respective number of questions per subtopic) are produced at the subtopic level. These scores are reported only as a general indicator of subtopic performance. Because the level of item difficulty and the number of items vary across subtopics, strict score comparisons should not be made across subtopics, nor should subtopic scores be used to make inferences about specific performance outcomes.

A sample individual report is included in Appendix C of this guide.

Roster Reports

The roster report is a Microsoft Excel file that contains score results for each of a school’s students who tested in a given testing window. The roster contains the following information: student name, school code, program year, time taken to complete the exam, overall and domain-level scaled score (SS), scaled score standard error of measurement (error), and percentile rank (%tile). The roster also contains percent-correct scores for each subtopic.

School/College of Pharmacy Reports

School/college-level reports include summary information at the cohort level. Mean scaled scores and their corresponding percentile rank scores (based on the norm reference group) are reported at the overall- and four domain-levels. Subtopic mean percent-correct scores and respective number of questions are also reported at the cohort level.

A sample school report is included in Appendix D of this guide.
Accessing and Understanding PCOA Scores

Understanding PCOA Results

PCOA score results provide measures of foundational knowledge in the didactic PharmD curriculum. Student-level score reports provide personalized, comparative information for participating students. School/college score reports provide aggregated results at the institutional level. The PCOA is designed to yield data that can be used to compare performance within a student cohort and across cohorts, such as to make dual pathway comparisons or comparisons to peer programs. PCOA results can be used to document change in student performance after an intervention and can serve as an independent measure for student portfolios.

Comparisons in outcomes between students, schools, and across time should only be made based on scaled scores. Percent-correct scores should not be used in any score comparisons because these scores are not equated, meaning that they do not take into account differences in item difficulty across test forms. NABP makes full effort to create PCOA test forms comparable in difficulty overall and at the domain level, but because each test form is unique, there may still be some variation. The scaled score is adjusted for any difference in difficulty across forms and therefore “levels the field” so that scores can be compared across different test forms without any confounds. Because of the limited utility of percent-correct scores, they are not reported for the overall exam or the four primary content domains.

Currently, subtopic scores are not placed on a common scaled score metric. To provide schools and students with some general indication of performance at the subtopic level, subtopic percent-correct scores are reported. However, these percent-correct scores should be interpreted with caution.

Information regarding the norm reference group is included with PCOA school/college of pharmacy reports.

Question and Exam Development

Questions (items) for the PCOA are written, reviewed, and approved by large, diverse committees of subject matter experts (SMEs) that serve as faculty at accredited US schools/colleges of pharmacy. Prior to being accepted as an item writer, SMEs are selected based upon academic and professional credentials. Committees of SMEs are routinely evaluated for representativeness and qualifications regarding geographic location, school/college of pharmacy affiliation, academic specialization and training, and demographics such as gender and ethnicity. Prior to writing items, SMEs receive thorough training on item development as outlined in professional guidelines for test development.

Committee item reviewers are experienced item writers whose role is to review and edit items developed for the PCOA. In accordance with professional standards, there is intentional, minimal overlap between item writers and item reviewers. This policy serves to protect tests from unintended bias.

PCOA forms are assembled to meet numerous pre-specified psychometric and statistical targets. These include, but are not limited to, item count, form-level difficulty, form-level reliability, and test information and test characteristic curves. Each test form aligns to the PCOA blueprint and therefore meets all content requirements.

Technical aspects of the PCOA are aligned with standards for professional test development. Prior to being selected to appear on an operational exam form, all questions are subjected to review by a committee of SMEs for the purpose of screening for enemy items (unintended cluing between items and/or content overlap) and to verify the item keys (answers). Forms are subject to various reviews prior to being approved for administration: psychometric review, editorial review, SME review, and overall committee review.

Validity Framework

The usefulness and interpretation of outcome measures (scores) are embedded in the assessment’s psychometric framework, which includes test design, item development, form assembly, data analyses, scoring, and reporting. An integral component of the PCOA’s content validity argument is the triangulation between outcomes from the content (curriculum) survey, the PCOA blueprint’s domains and weights, and the adherence to those weights in the assembly of operational test forms. All questions are written and reviewed by a wide range of SMEs who are faculty at accredited US schools/colleges of pharmacy, and all exam forms are reviewed and approved by committees of SMEs prior to being administered. Thus, the PCOA is tightly linked to the content and culture of pharmacy education.
**NABP Analyses**

At the conclusion of each test window, NABP routinely performs a key validation, which includes an option/distractor analysis of every operational item, computation of item difficulty and discrimination indices, fit analyses, computation of item- and form-level reliability indices, a time analysis, and data forensics. Data forensics are used to review response data for inconsistent or unusual responses, over-endorsement of an option, unusual response times, and/or significant difference in performance on operational versus pretest items. NABP archives all assessment data in the event that a test record may need to be retrieved or rescored.

In addition to analyses on operational items, NABP also performs a comprehensive item analysis on all pretest items. Pretest items are non-scored items that are included in the examination form for the purpose of evaluating measures of item performance. Pretest status is not detectable by the examinee. In other words, an examinee cannot differentiate between which items will contribute to their score and those that will not. Items that meet or exceed certain psychometric and statistical targets are promoted to operational status and become available for inclusion on future operational test forms. Items that fail to meet such targets are either sent for revision or are deleted. All revised items (if selected) are pretested on a future PCOA form.
Appendices

Appendix A: Glossary of Important Terms for the PCOA Scores

**Scaled Scores:** A scaled score is the result of applying a mathematical transformation to a raw (e.g., number correct) score. Placing scores on an established scale removes extraneous effects due to differences in exam form difficulty and thus allows end users to easily interpret scores from different test forms and/or different administrations. PCOA scaled scores range from 0 to 700, inclusively, and can be compared across administrations as well as between major content areas. For example, a student scoring 200 on Pharmaceutical Sciences and 250 on Basic Biomedical Sciences demonstrates greater proficiency in Basic Biomedical Sciences than Pharmaceutical Sciences.

**Scaled Score Standard Error of Measurement:** Standard error of measurement (SEM) for overall and domain-level scaled scores (SS) can assist with meaningful score interpretation. SEM is a measure that can be used to establish confidence bands around an examinee’s scaled score. A confidence band is an interval that is expected to contain the examinee’s true ability score with a certain degree of confidence. Estimates for confidence bands can be established by calculating $SS \pm 2 \times SEM$ (95% confidence) and $SS \pm 1 \times SEM$ (68% confidence). In these examples, one may infer (with 95% or 68% confidence, respectively) that a student’s true ability score is located within the respective score ranges. SEM is especially useful when evaluating the magnitude or significance of score differences. When comparing two test scores, the presence or absence of overlap between the confidence bands should be evaluated. If the confidence bands for two test scores do not overlap, there is evidence for a meaningful difference in test scores (i.e., the test score difference is not primarily attributable to measurement error). Measurement error is not constant across the test score range; very high and very low scores will have more measurement error (and hence higher SEM) than scores near the middle of the score range.

**% Correct Scores:** The percent-correct score indicates the percentage of items answered correctly. It is not adjusted for differences in item difficulty across forms and, as such, should be interpreted with caution. NABP reports percent-correct scores for the subtopic section of both the individual (student) and school/college reports.

**Percentile Rank Scores:** Percentile rank scores indicate a relative rank of proficiency with respect to a well-defined, representative reference group. For example, if a first-year student’s Percentile for Program Year score is 68, then this implies that the student performed equally or better than 68% of all other first-year students in the norm reference group.

**PCOA Form Assembly:** The PCOA is assembled to meet very specific content and psychometric targets. Content targets include the number of items per main content domain and subdomain. Item counts align with the PCOA blueprint.

Prior to scoring, a key validation is performed. All operational data (scored items) are analyzed for performance and model fit. If an item is flagged for aberrant performance, it is sent to a SME for review and key verification. All exam data are screened for anomalous records, and when appropriate, schools are notified when anomalies are detected. Data are also subjected to extensive data forensic analyses.
### Appendix B: Important Dates for the 2019 PCOA

<table>
<thead>
<tr>
<th>Testing Window</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First Testing Window:</strong></td>
<td><strong>January 14, 2019 – February 15, 2019</strong></td>
</tr>
<tr>
<td>Registration Closes for All Schools/Colleges</td>
<td>October 16, 2018</td>
</tr>
<tr>
<td>Student Registration Closes</td>
<td>November 15, 2018</td>
</tr>
<tr>
<td>Student Rosters Completed by:</td>
<td>November 30, 2018</td>
</tr>
<tr>
<td>ADA Requests Submitted by School to NABP by:</td>
<td>November 30, 2018</td>
</tr>
<tr>
<td><strong>Second Testing Window:</strong></td>
<td><strong>April 8, 2019 – May 17, 2019</strong></td>
</tr>
<tr>
<td>Registration Closes for All Schools/Colleges</td>
<td>January 8, 2019</td>
</tr>
<tr>
<td>Student Registration Closes</td>
<td>February 7, 2019</td>
</tr>
<tr>
<td>Student Rosters Completed by:</td>
<td>February 22, 2019</td>
</tr>
<tr>
<td>ADA Requests Submitted by School to NABP by:</td>
<td>February 22, 2019</td>
</tr>
<tr>
<td><strong>Third Testing Window:</strong></td>
<td><strong>June 17, 2019 – June 28, 2019</strong></td>
</tr>
<tr>
<td>Registration Closes for All Schools/Colleges</td>
<td>March 19, 2019</td>
</tr>
<tr>
<td>Student Registration Closes</td>
<td>April 18, 2019</td>
</tr>
<tr>
<td>Student Rosters Completed by:</td>
<td>May 3, 2019</td>
</tr>
<tr>
<td>ADA Requests Submitted by School to NABP by:</td>
<td>May 3, 2019</td>
</tr>
<tr>
<td><strong>Fourth Testing Window:</strong></td>
<td><strong>August 19, 2019 – September 13, 2019</strong></td>
</tr>
<tr>
<td>Registration Closes for All Schools/Colleges</td>
<td>May 21, 2019</td>
</tr>
<tr>
<td>Student Registration Closes</td>
<td>June 20, 2019</td>
</tr>
<tr>
<td>Student Rosters Completed by:</td>
<td>July 5, 2019</td>
</tr>
<tr>
<td>ADA Requests Submitted by School to NABP by:</td>
<td>July 5, 2019</td>
</tr>
<tr>
<td><strong>Fifth Testing Window:</strong></td>
<td><strong>November 11, 2019 – December 13, 2019</strong></td>
</tr>
<tr>
<td>Registration Closes for All Schools/Colleges</td>
<td>August 13, 2019</td>
</tr>
<tr>
<td>Student Registration Closes</td>
<td>September 12, 2019</td>
</tr>
<tr>
<td>Student Rosters Completed by:</td>
<td>September 27, 2019</td>
</tr>
<tr>
<td>ADA Requests Submitted by School to NABP by:</td>
<td>September 27, 2019</td>
</tr>
</tbody>
</table>
Your PCOA® scaled scores for the overall examination and each of the four main content areas are included in the figure and table above. Examination scaled scores range from 0 to 700. The score report includes confidence bands, which indicate the degree of measurement precision in each of your test scores. When a confidence band overlaps two test scores, then by comparison, the performance in those areas should be considered similar.

Also included in the report are average scores for a large, diverse, national group of students who have taken the PCOA (reference group). If you are designated as a student in their first, second, or third program year, your reference group is the national group of students who took the PCOA in the same program year as you. If you are a fourth-year student, your scores will be referenced against scores from the national group of third-year students. Third-year students test at or near the end of the didactic curriculum. The number of students testing after completion of the didactic portion of the curriculum is not large enough to create an independent reference group. Your scores and associated confidence bands can be used to gauge your performance relative to the reference group. If there is no overlap between the confidence band for one of your scores and its corresponding reference-group national average, then you may conclude that you performed differently than your peers. However, if the reference group national average falls largely within your score’s confidence band, then your performance should be considered similar to the reference group.

The percentile ranks for your overall score and content area scores are also included in the score report above. Percentile ranks are reported in relation to the reference group. For example, a percentile rank of 68 indicates that you scored as well as or better than 68% of your national peer group.
Percent-correct scores are reported below for each subtopic along with the number of items in each subtopic. These scores are reported only as a general indicator of subtopic performance. Because the level of item difficulty and the number of items vary across subtopics, strict score comparisons should not be made across subtopics, nor should subtopic scores be used to make inferences about specific performance outcomes.

<table>
<thead>
<tr>
<th>Sub Topics</th>
<th># of Items</th>
<th>% Correct</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic Biomedical Sciences</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physiology</td>
<td>6</td>
<td>44</td>
</tr>
<tr>
<td>Biochemistry</td>
<td>8</td>
<td>75</td>
</tr>
<tr>
<td>Microbiology Related to Human Disease</td>
<td>2</td>
<td>60</td>
</tr>
<tr>
<td>Immunology</td>
<td>4</td>
<td>25</td>
</tr>
<tr>
<td><strong>Pharmaceutical Sciences</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicinal Chemistry</td>
<td>15</td>
<td>42</td>
</tr>
<tr>
<td>Pharmacology and Toxicology</td>
<td>17</td>
<td>33</td>
</tr>
<tr>
<td>Pharmacognosy and Dietary Supplements</td>
<td>2</td>
<td>100</td>
</tr>
<tr>
<td>Pharmaceutics/Biopharmaceutics</td>
<td>12</td>
<td>54</td>
</tr>
<tr>
<td>Pharmacokinetics</td>
<td>8</td>
<td>20</td>
</tr>
<tr>
<td>Pharmacogenomics and Genetics</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Sterile and Nonsterile Compounding</td>
<td>6</td>
<td>43</td>
</tr>
<tr>
<td><strong>Social/Behavioral/Administrative Sciences</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Care Delivery Systems and Public Health</td>
<td>6</td>
<td>71</td>
</tr>
<tr>
<td>Population-Based Care and Pharmacoepidemiology</td>
<td>3</td>
<td>67</td>
</tr>
<tr>
<td>Economic and Humanistic Outcomes of Health Care Delivery</td>
<td>2</td>
<td>33</td>
</tr>
<tr>
<td>Pharmacy Practice Management</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Pharmacy Law and Regulatory Affairs</td>
<td>5</td>
<td>80</td>
</tr>
<tr>
<td>Biostatistics and Research Design</td>
<td>3</td>
<td>80</td>
</tr>
<tr>
<td>Ethical Decision Making</td>
<td>3</td>
<td>50</td>
</tr>
<tr>
<td>Professional Communication</td>
<td>7</td>
<td>67</td>
</tr>
<tr>
<td>Social and Behavioral Aspects of Pharmacy Practice</td>
<td>3</td>
<td>100</td>
</tr>
<tr>
<td>Medication Dispensing and Distribution Systems</td>
<td>6</td>
<td>71</td>
</tr>
<tr>
<td><strong>Clinical Sciences</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evidence-based Practice</td>
<td>10</td>
<td>71</td>
</tr>
<tr>
<td>Clinical Pathophysiology</td>
<td>8</td>
<td>67</td>
</tr>
<tr>
<td>Clinical Pharmacokinetics</td>
<td>5</td>
<td>58</td>
</tr>
<tr>
<td>Clinical Pharmacogenomics</td>
<td>2</td>
<td>67</td>
</tr>
<tr>
<td>Disease Prevention and Population Health</td>
<td>4</td>
<td>100</td>
</tr>
<tr>
<td>Patient Assessment</td>
<td>9</td>
<td>71</td>
</tr>
<tr>
<td>Clinical Pharmacology and Therapeutic Decision Making</td>
<td>32</td>
<td>50</td>
</tr>
</tbody>
</table>
Appendix D: School/College Score Report Sample

Pharmacy Curriculum Outcomes Assessment® (PCOA®) School/College of Pharmacy Report
2017 Window 2 (April/May)

School Name: Sample University

The following tables and graphs summarize your students’ performance on the PCOA®. To date in 2017, a total of 16,709 students have taken the PCOA, with 1,624 students reporting as first year, 1,933 students as second year, 12,964 students as third year and 188 students as fourth year.

The School/College Score Means section on Page 2 includes your school’s mean scaled scores for the total examination as well as the mean scaled scores for each of the four major content areas. The score report charts include confidence intervals, which indicate the degree of sampling error in each of your mean test scores. When a confidence interval overlaps two test score means, then by comparison, performance in those areas should be considered similar.

Scaled scores take into account the difficulty of the items in the major content areas. These scores range from 0 to 700 and can be compared across administrations. Scaled scores can also be compared between the major content areas, such that a student scoring 200 on Pharmaceutical Sciences and 250 on Basic Sciences demonstrated greater proficiency in Basic Biomedical Sciences than Pharmaceutical Sciences.

Also included in the report (on Page 2) are mean scaled scores for all students in a normed reference group. The normed reference group consists of a large, national, diverse group of students from United States colleges/schools of pharmacy. Based on data from 2016 through 2017, the norm group consists of approximately 18,070 students that collectively generalize to the population of pharmacy students. The use of reference groups in score reporting permits meaningful comparisons between the performances of current examinees to the performance of a national representative group.

Your school’s mean scores and associated confidence intervals can be used to gauge your school’s performance relative to national performance. If there is very little or no overlap between your school’s confidence interval and the corresponding reference group mean, then you may conclude that your school performed differently in that area than the normed reference group. However, if the normed reference group mean falls largely within your school’s confidence interval, then your school’s performance in that area should be considered similar to the national average.

The percentile ranks of your school’s mean scaled scores (overall and at the major domain level) in the normed reference group are reported on Page 2. Individual percentile ranks (supplied in the student report) provide performance information in relation to other students within the normed reference group. The percentile rank for your school’s average scaled score indicates the standing of your school’s average student in the normed reference group. For example, if your school’s percentile rank for third-year students is 60, this implies that your average third-year student performed equally or better than 60% of all other third-year students in the normed reference group.

The School/College Subtopic Mean Percent Correct Scores section on Page 3 reports your students’ performance (broken out by program year) at the subtopic level. These scores are reported only as a general indicator of subtopic performance. Because the level of item difficulty and the number of items vary across subtopics, strict score comparisons should not be made using subtopic scores, nor should subtopic scores be used to make inferences about specific performance outcomes.
### School/College Score Means

<table>
<thead>
<tr>
<th>Year</th>
<th>Your School</th>
<th>Reference Group</th>
<th>Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yr 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yr 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yr 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yr 4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Total Score

<table>
<thead>
<tr>
<th>P Year</th>
<th>Year 1 N:</th>
<th>Year 2 N:</th>
<th>Year 3 N:</th>
<th>Year 4 N:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>15</td>
<td>15</td>
<td>15</td>
<td>15</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P Year</th>
<th>Total Score</th>
<th>Reference Grp</th>
<th>Percentile Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yr 1</td>
<td>289</td>
<td>277</td>
<td>50</td>
</tr>
<tr>
<td>Yr 2</td>
<td>330</td>
<td>331</td>
<td>50</td>
</tr>
<tr>
<td>Yr 3</td>
<td>351</td>
<td>358</td>
<td>50</td>
</tr>
<tr>
<td>Yr 4</td>
<td>346</td>
<td>362</td>
<td>50</td>
</tr>
</tbody>
</table>

#### Area 1: Basic Biomedical Sciences

<table>
<thead>
<tr>
<th>P Year</th>
<th>Total Score</th>
<th>Reference Grp</th>
<th>Percentile Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yr 1</td>
<td>329</td>
<td>320</td>
<td>50</td>
</tr>
<tr>
<td>Yr 2</td>
<td>358</td>
<td>349</td>
<td>50</td>
</tr>
<tr>
<td>Yr 3</td>
<td>351</td>
<td>348</td>
<td>50</td>
</tr>
<tr>
<td>Yr 4</td>
<td>315</td>
<td>340</td>
<td>50</td>
</tr>
</tbody>
</table>

#### Area 2: Pharmaceutical Sciences

<table>
<thead>
<tr>
<th>P Year</th>
<th>Total Score</th>
<th>Reference Grp</th>
<th>Percentile Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yr 1</td>
<td>276</td>
<td>281</td>
<td>50</td>
</tr>
<tr>
<td>Yr 2</td>
<td>316</td>
<td>332</td>
<td>50</td>
</tr>
<tr>
<td>Yr 3</td>
<td>337</td>
<td>357</td>
<td>50</td>
</tr>
<tr>
<td>Yr 4</td>
<td>339</td>
<td>356</td>
<td>50</td>
</tr>
</tbody>
</table>

#### Area 3: Social/Behavioral/Administrative Sciences

<table>
<thead>
<tr>
<th>P Year</th>
<th>Total Score</th>
<th>Reference Grp</th>
<th>Percentile Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yr 1</td>
<td>316</td>
<td>278</td>
<td>50</td>
</tr>
<tr>
<td>Yr 2</td>
<td>357</td>
<td>337</td>
<td>50</td>
</tr>
<tr>
<td>Yr 3</td>
<td>365</td>
<td>358</td>
<td>50</td>
</tr>
<tr>
<td>Yr 4</td>
<td>358</td>
<td>361</td>
<td>50</td>
</tr>
</tbody>
</table>

#### Area 4: Clinical Sciences

<table>
<thead>
<tr>
<th>P Year</th>
<th>Total Score</th>
<th>Reference Grp</th>
<th>Percentile Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yr 1</td>
<td>263</td>
<td>252</td>
<td>50</td>
</tr>
<tr>
<td>Yr 2</td>
<td>314</td>
<td>320</td>
<td>50</td>
</tr>
<tr>
<td>Yr 3</td>
<td>359</td>
<td>368</td>
<td>50</td>
</tr>
<tr>
<td>Yr 4</td>
<td>366</td>
<td>389</td>
<td>50</td>
</tr>
</tbody>
</table>
### School/College Subtopic Mean Percent Correct Scores

<table>
<thead>
<tr>
<th>Sub Topics</th>
<th># of Items</th>
<th>School</th>
<th>School</th>
<th>School</th>
<th>School</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic Biomedical Sciences</strong></td>
<td>20</td>
<td>School</td>
<td>School</td>
<td>School</td>
<td>School</td>
</tr>
<tr>
<td>Physiology</td>
<td>6</td>
<td>58</td>
<td>58</td>
<td>58</td>
<td>58</td>
</tr>
<tr>
<td>Biochemistry</td>
<td>8</td>
<td>44</td>
<td>44</td>
<td>44</td>
<td>44</td>
</tr>
<tr>
<td>Microbiology Related to Human Disease</td>
<td>2</td>
<td>55</td>
<td>55</td>
<td>55</td>
<td>55</td>
</tr>
<tr>
<td>Immunology</td>
<td>4</td>
<td>52</td>
<td>52</td>
<td>52</td>
<td>52</td>
</tr>
<tr>
<td><strong>Pharmaceutical Sciences</strong></td>
<td>66</td>
<td>School</td>
<td>School</td>
<td>School</td>
<td>School</td>
</tr>
<tr>
<td>Medicinal Chemistry</td>
<td>15</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>Pharmacology and Toxicology</td>
<td>17</td>
<td>56</td>
<td>56</td>
<td>56</td>
<td>56</td>
</tr>
<tr>
<td>Pharmacognosy and Dietary Supplements</td>
<td>2</td>
<td>58</td>
<td>58</td>
<td>58</td>
<td>58</td>
</tr>
<tr>
<td>Pharmaceutics/Biopharmaceutics</td>
<td>12</td>
<td>74</td>
<td>74</td>
<td>74</td>
<td>74</td>
</tr>
<tr>
<td>Pharmacokinetics</td>
<td>8</td>
<td>69</td>
<td>69</td>
<td>69</td>
<td>69</td>
</tr>
<tr>
<td>Pharmacogenomics and Genetics</td>
<td>6</td>
<td>47</td>
<td>47</td>
<td>47</td>
<td>47</td>
</tr>
<tr>
<td>Sterile and Nonsterile Compounding</td>
<td>6</td>
<td>31</td>
<td>31</td>
<td>31</td>
<td>31</td>
</tr>
<tr>
<td><strong>Social/Behavioral/Administrative Sciences</strong></td>
<td>44</td>
<td>School</td>
<td>School</td>
<td>School</td>
<td>School</td>
</tr>
<tr>
<td>Health Care Delivery Systems and Public Health</td>
<td>6</td>
<td>51</td>
<td>51</td>
<td>51</td>
<td>51</td>
</tr>
<tr>
<td>Population-Based Care and Pharmacoepidemiology</td>
<td>3</td>
<td>67</td>
<td>67</td>
<td>67</td>
<td>67</td>
</tr>
<tr>
<td>Economic and Humanistic Outcomes of Health Care Delivery</td>
<td>2</td>
<td>65</td>
<td>65</td>
<td>65</td>
<td>65</td>
</tr>
<tr>
<td>Pharmacy Practice Management</td>
<td>6</td>
<td>63</td>
<td>63</td>
<td>63</td>
<td>63</td>
</tr>
<tr>
<td>Pharmacy Law and Regulatory Affairs</td>
<td>5</td>
<td>56</td>
<td>56</td>
<td>56</td>
<td>56</td>
</tr>
<tr>
<td>Biostatistics and Research Design</td>
<td>3</td>
<td>83</td>
<td>83</td>
<td>83</td>
<td>83</td>
</tr>
<tr>
<td>Ethical Decision Making</td>
<td>3</td>
<td>67</td>
<td>67</td>
<td>67</td>
<td>67</td>
</tr>
<tr>
<td>Professional Communication</td>
<td>7</td>
<td>68</td>
<td>68</td>
<td>68</td>
<td>68</td>
</tr>
<tr>
<td>Social and Behavioral Aspects of Pharmacy Practice</td>
<td>3</td>
<td>78</td>
<td>78</td>
<td>78</td>
<td>78</td>
</tr>
<tr>
<td>Medication Dispensing and Distribution Systems</td>
<td>6</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
</tr>
<tr>
<td><strong>Clinical Sciences</strong></td>
<td>70</td>
<td>School</td>
<td>School</td>
<td>School</td>
<td>School</td>
</tr>
<tr>
<td>Evidence-based Practice</td>
<td>10</td>
<td>62</td>
<td>62</td>
<td>62</td>
<td>62</td>
</tr>
<tr>
<td>Clinical Pathophysiology</td>
<td>8</td>
<td>61</td>
<td>61</td>
<td>61</td>
<td>61</td>
</tr>
<tr>
<td>Clinical Pharmacokinetics</td>
<td>5</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>Clinical Pharmacogenomics</td>
<td>2</td>
<td>58</td>
<td>58</td>
<td>58</td>
<td>58</td>
</tr>
<tr>
<td>Disease Prevention and Population Health</td>
<td>4</td>
<td>58</td>
<td>58</td>
<td>58</td>
<td>58</td>
</tr>
<tr>
<td>Patient Assessment</td>
<td>9</td>
<td>83</td>
<td>83</td>
<td>83</td>
<td>83</td>
</tr>
<tr>
<td>Clinical Pharmacology and Therapeutic Decision Making</td>
<td>32</td>
<td>73</td>
<td>73</td>
<td>73</td>
<td>73</td>
</tr>
</tbody>
</table>
Pharmacy Curriculum Outcomes Assessment® (PCOA®) Registration Form

This form must be submitted prior to the close of registration for each window as noted below. Late registrations will not be processed.

School/College of Pharmacy

Please select a date(s) within the following five 2019 administration windows:

- January 14 – February 15 (register by October 16, 2018)
- April 8 – May 17 (register by January 8, 2019)
- June 17 – June 28 (register by March 19, 2019)
- August 19 – September 13 (register by May 21, 2019)
- November 11 – December 13 (register by August 13, 2019)

Date and Time for Your Assessment Administration
“Time” is when you would like your assessment to begin. The testing location, including the registration area, should be available one hour prior to your scheduled assessment start time.

Date Time Time Zone

On-site Assessment Location(s):

Building Name and Room(s) – minimum of a four-hour time slot

Building Physical Street Address
School/College of Pharmacy On-site Contact

Name: ___________________________________________________________

Title: __________________________________________________________________

Address: __________________________________________________________________

Address 2: __________________________________________________________________

City, State, Zip: __________________________________________________________________

Phone: ___________________________ Email: ______________________________________

On-site technical representative: ________________________________________________

Phone: ___________________________ Email: ______________________________________

Estimated Number of Students Participating by Program Year:

Note: To ensure appropriate reporting of scores and assessment-related invoicing, please indicate any students nearing the end of their didactic curriculum as P3.

P1: _____ + P2: _____ + P4: _____ x $75 = $ ________

P3: ______ (No fee for first-time P3 test takers.)

Report scores to the Accreditation Council for Pharmacy Education?  Yes ☐  No ☐

Will any candidates need Americans with Disabilities Act (ADA) testing accommodations?

☐ Yes ☐ No

If yes, approximately how many? ______

Note: Please refer to the PCOA Registration and Administration Guide for Schools and Colleges of Pharmacy for details about ADA accommodations for students. It is the responsibility of the student to submit the ADA request form to the school. Schools must complete the academic/college statement section of the ADA request forms and completed forms (all three sections, including Individual’s Statement, Practitioner’s Statement and Diagnostic Results, and Academic/College Information) must be received by NABP from the school/college 45 days prior to the start of the testing window. Failure to submit the appropriate documentation will result in unavailability of testing accommodations.
Payment Information
If applicable, NABP will invoice you after the completion of your PCOA. If you would like to send a purchase order prior to your administration, NABP will invoice against your purchase order.

☐ Invoice on-site assessment contact

☐ Please send invoice to the following:

Name: ________________________________________________________________

Title:  ________________________________________________________________

Address: ______________________________________________________________

Address 2: ____________________________________________________________

City, State, Zip: _______________________________________________________

Email: ________________________________________________________________

Instructions for Submitting the PCOA Registration Form
• Please download, complete, save, and send the form via email to PCOA@nabp.pharmacy.
• Attn: Nancy Rutter, FPGEC/PCOA Program Analyst